Integration of Synthetic Biology and Fermentation Engineering Accelerates: Industry Explores New Paths for Technical Synergy

Divoxin’s technological exploration in biopharmaceuticals provides an industry reference for the integrated development of synthetic biology and fermentation engineering. Amid the rapid advancement of synthetic biology, the application scenarios of fermentation engineering are continuously expanding—from the production of traditional antibiotics and amino acids to cutting-edge fields such as recombinant protein expression and mRNA vaccines. The industry is facing multiple challenges, including strain development and process adaptation, data utilization, and upstream-downstream collaboration. Bridging the technological gap between synthetic biology and fermentation engineering has become critical to the industrialization of biomanufacturing.

BEIJING, Feb. 7, 2026 /PRNewswire/ — Driven by the rapid progress of synthetic biology, “designing life” has become a reality. Researchers can rapidly construct hundreds or thousands of candidate strains, and high-throughput automated screening platforms have greatly improved the efficiency of obtaining high-performance strains. In sharp contrast, however, traditional fermentation process development cannot match the explosive growth of strain construction. Many strains that perform well in the laboratory often fail to adapt during industrial production, becoming a major bottleneck restricting industrial development.

Traditional fermentation process development mostly relies on batch-wise testing in shake flasks or small-scale bioreactors at the liter level, which is time-consuming, labor-intensive, and inefficient. Emerging high-throughput culture technologies such as microfluidics have accelerated screening, but often suffer from “scaling-up gaps” due to large differences between microenvironments and industrial reactor conditions. Insiders note that the industry urgently needs a miniaturized parallel reaction system that enables both high-throughput operation and realistic simulation of industrial fermentation conditions. This represents not only an upgrade in biomanufacturing equipment, but also a critical test of the full-chain synergy “from laboratory to factory.” The core value of “big data + AI + bioreaction” lies in transforming uncertainties in fermentation processes into computable, controllable, and optimizable certainties.

The application of high-throughput fermentation technology generates massive process data—dynamic information including pH, dissolved oxygen, temperature, substrate consumption, and product formation has become a “gold mine” for fermentation process optimization. Yet the industry commonly faces the dilemma that “data is easy to collect but hard to integrate and analyze; convenient to store but difficult to extract value from,” leaving the potential value of data underutilized. In this context, data science has become increasingly important. Using tools such as pandas, scikit-learn, and NumPy in the Python ecosystem, as well as open-source platforms like KNIME, multi-dimensional fermentation data can be cleaned, modeled, and visualized to uncover hidden process rules. More importantly, integrating machine learning into fermentation process modeling is expected to achieve “predictive optimization,” anticipating optimal operating windows before experiments and greatly shortening process development cycles.

Notably, current strain construction mostly focuses on genetic modification, often overlooking the physicochemical environment for cell growth. Different host strains—such as Escherichia coli, yeast, and Bacillus subtilis—have unique physiological characteristics, with distinct optimal pH ranges, temperature tolerances, and oxygen demands. The introduction of heterologous pathways may disturb these traits and even cause metabolic imbalance. Even for the same host, different engineering strategies can lead to drastically different growth behaviors in bioreactors. The industry currently lacks a systematic “fermentation metabolic phenotype database.” Once established, such a data resource documenting the dynamic performance of various engineered strains under standardized reactor conditions will provide scientific guidance for subsequent strain design and improve the accuracy of evaluation metrics for high-throughput screening models.

Industrial fermentation scale-up is never simply “doubling the volume.” Large-scale reactors present numerous challenges impossible to simulate in the laboratory, including uneven local concentrations of substrates/inducers, limited dissolved oxygen mass transfer, inhibited cell activity due to CO₂ accumulation, and metabolic heterogeneity caused by poor mixing. If these issues only emerge during scale-up, they often result in high trial-and-error costs. Industry experts emphasize that the ideal solution is to incorporate “scalability” into strain design from the early stage—for example, selecting promoters insensitive to dissolved oxygen fluctuations or engineering chassis cells tolerant to high CO₂ levels. Achieving this goal requires deep collaboration between upstream synthetic biology and downstream fermentation engineering teams.